Novartis Oncology Advancements: Key Trial Findi...

By HEOR Staff Writer

May 22, 2026

Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinfo...
Baxfendy Hypertension Treatment: FDA Approves First-in-Class Aldosterone Synt...
Trastuzumab-Deruxtecan Reimbursement: A Careful Evaluation of Cost-Effectiven...
Portugal Health Spending 2025 Reaches Record €4.417 Billion Amid Rising Demand
PSA Response Improvement: Promising Data from Pluvicto in mHSPC Treatment
Financing Boosts Vaccine Manufacturing Africa: New Facility to Enhance Local ...
Enhertu Breast Cancer Treatment Gains FDA Approval in Neoadjuvant and Adjuvan...
Dynamic Risk Stratification in Thromboembolism Prevention for Cancer Patients
Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial P...
Portugal Cannabis Market Decline: Analyzing the Impact of Licensing Reductions
NICE Approves Durvalumab for Gastric Cancer Treatment
Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients
Global Growth and Challenges in Pharmacy Vaccination Training